IDC MarketScape highlights Siemens' digital twin, AI-enabled portfolio and Smart Lab Ecosystem as key strengths.
Siemens announced that IDC MarketScape has named it a Leader in its 2026 assessment of life sciences R&D lab technology and consulting providers. The recognition appears in the IDC MarketScape: Worldwide Life Sciences R&D Lab of the Future Technology Solutions and Consulting Services 2026 Vendor Assessment. The recognition comes as life sciences companies face mounting pressure to modernize fragmented lab systems while meeting increasingly complex regulatory requirements.
IDC MarketScape assessed vendors based on their current capabilities and the strength of their strategy for the next three to five years. According to the report, “Siemens’ differentiators include its end-to-end coverage of the pharma value chain, from R&D, pilot, scale-up through commercial manufacturing to buildings and electrification, its comprehensive digital twin and AI-enabled portfolio, its open and vendor-agnostic Smart Lab Ecosystem, and its Enterprise Recipe Management approach built on the ISA-88 standard.”
Siemens defines the Lab of the Future as a connected, AI-enabled scientific environment where data, models and workflows move seamlessly across discovery, development, scale-up and manufacturing.
In another engagement noted in the report, “AstraZeneca worked with Siemens’ gPROMS-formulated products process modeling technology to explore the design of a tablet manufacturing process, constructing a flowsheet model of a dry granulation and tableting process and running over 3,000 virtual experiments to quantify the criticality of material properties and process parameters on product quality attributes, generating significant savings in time, resources, and materials versus physical experimentation.”
The report also noted several strengths, noting Siemens’ Smart Lab Ecosystem (SLE), “a modular, vendor-agnostic infrastructure kit that allows flexible plug -and-play composition of room segments, devices, and sensors to create adaptable research and laboratory spaces. Independently tested with the University of Applied Sciences Luzern in Switzerland under ‘Project PEARL,’ Siemens reports the Smart Lab Ecosystem delivers a 31 percent superior local air change rate, 29 percent faster particle removal, and 45 percent better ventilation efficiency, alongside up to 60 percent faster lab design and construction and up to 80 percent reduction in changeover time between lab configurations.“
These engagements build on Siemens’ broader AI strategy for life sciences. Following its 2025 acquisition of Dotmatics, Siemens extended its digital thread further upstream into drug discovery, creating a unique connection between scientific research and industrial execution. Through Dotmatics Luma, an AI-native scientific intelligence platform, researchers can connect laboratory instruments, scientific applications and enterprise systems into a unified data environment that supports faster and more informed decisions throughout the product lifecycle. Dotmatics Luma is part of Siemens Xcelerator, Siemens’ open digital business platform that unifies its life sciences offering across the value chain. Siemens’ portfolio for the life sciences industry spans the entire pharmaceutical value chain, from molecule to market, enabling a continuous digital thread across product and production lifecycles.
For more information, visit siemens.com.
